Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib combined with CAPEOX as neoadjuvant treatment for locally advanced colorectal cancer
ChiCTR2300077712Phase 2Not yet recruiting
- Sponsor
- Jingzhou Central Hospital
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, capecitabine and oxaliplatin in colorectal adenocarcinoma, sponsored by Jingzhou Central Hospital. Primary endpoint: Pathological complete response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
fruquintinibcapecitabineoxaliplatin
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300077712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077712.